Literature DB >> 10395220

Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders.

A Seretti1, C Cusin, E Lattuada, D Di Bella, M Catalano, E Smeraldi.   

Abstract

Disturbances of the serotoninergic neutrotransmitter system have been implicated in the pathogenesis of mood disorders. A functional polymorphism in the upstream regulatory region of the serotonin transporter gene (5-HTTLPR) has been recently reported to be associated with both unipolar and bipolar disorder. In this study, we investigated the possibility that the 5-HTTLPR might be associated with depressive symptomatology in a sample of mood disorder subjects. One hundred and thirty-two psychiatric inpatients affected by major depressive (n = 67) and bipolar (n = 65) disorder (DSM-IV) were assessed at admission by the Hamilton Depression Rating Scale (HAMD-21, divided into Core, Sleep, Activity, Psychic anxiety, Somatic anxiety and Delusion clusters) and were typed using PCR techniques. The only prior treatment permitted was low dose benzodiazepines (<5 mg diazepam or equivalent); no prior (<2 weeks) antidepressant or neuroleptic treatment was allowed. 5-HTTLPR variants were not associated with total depressive symptomatology as measured by HAMD. The short 5-HTTLPR variant was marginally associated with higher psychic anxiety scores (F = 7.11, d.f. = 1,262, P = 0.008). The association was stronger among bipolars and early onset subjects. 5-HTTLPR variants were not associated with the remaining symptom clusters. The upstream regulatory region of the serotonin transporter gene has not, therefore, a major influence on the depressive symptomatology in mood disorder subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395220     DOI: 10.1038/sj.mp.4000485

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  17 in total

Review 1.  Recent progress in the search for genes for bipolar disorder.

Authors:  J R Kelsoe
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.

Authors:  Albert Putzhammer; Anja Schoeler; Thomas Rohrmeier; Philipp Sand; Goeran Hajak; Peter Eichhammer
Journal:  Psychopharmacology (Berl)       Date:  2004-08-18       Impact factor: 4.530

3.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

4.  The serotonin transporter gene and startle response during nicotine deprivation.

Authors:  Jennifer A Minnix; Jason D Robinson; Cho Y Lam; Brian L Carter; Jennifer E Foreman; David J Vandenbergh; Gail E Tomlinson; David W Wetter; Paul M Cinciripini
Journal:  Biol Psychol       Date:  2010-10-01       Impact factor: 3.251

5.  Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility.

Authors:  Berna Tander; Sezgin Gunes; Omer Boke; Gamze Alayli; Nurten Kara; Hasan Bagci; Ferhan Canturk
Journal:  Rheumatol Int       Date:  2008-01-15       Impact factor: 2.631

6.  Serotonin transporter gene polymorphisms & obsessive-compulsive disorder.

Authors:  Humberto Nicolini
Journal:  Indian J Med Res       Date:  2010-12       Impact factor: 2.375

7.  Serotonin transporter gene polymorphism and psychiatric disorders: is there a link?

Authors:  Mushtaq A Margoob; Dhuha Mushtaq
Journal:  Indian J Psychiatry       Date:  2011-10       Impact factor: 1.759

8.  Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder.

Authors:  Shintaro Ogawa; Kotaro Hattori; Daimei Sasayama; Yuki Yokota; Ryo Matsumura; Junko Matsuo; Miho Ota; Hiroaki Hori; Toshiya Teraishi; Sumiko Yoshida; Takamasa Noda; Yoshiaki Ohashi; Hajime Sato; Teruhiko Higuchi; Nobutaka Motohashi; Hiroshi Kunugi
Journal:  Sci Rep       Date:  2015-01-15       Impact factor: 4.379

9.  Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder.

Authors:  Kiyokazu Atake; Reiji Yoshimura; Hikaru Hori; Asuka Katsuki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-03       Impact factor: 2.570

10.  Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study.

Authors:  Mushtaq A Margoob; Dhuha Mushtaq; Imtiyaz Murtza; Huda Mushtaq; Arif Ali
Journal:  Indian J Psychiatry       Date:  2008-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.